Alteogen announced on March 25 that it has signed an exclusive license agreement with the global pharmaceutical company Biogen for the development and commercialization of subcutaneous (SC) formulation biopharmaceuticals based on ALT-B4, which utilizes its Hybrozyme technology.


Exterior view of Alteogen headquarters in Yuseong District, Daejeon. Alteogen

Exterior view of Alteogen headquarters in Yuseong District, Daejeon. Alteogen

View original image

Under this agreement, Biogen will secure exclusive rights to develop and commercialize subcutaneous formulations of two biopharmaceutical products using Alteogen's ALT-B4.


Upon signing the contract, Alteogen will receive an upfront payment of 20 million dollars (approximately 30 billion won), and an additional upfront payment of 10 million dollars (approximately 15 billion won) when the development of the second product is initiated. The company may also receive up to 549 million dollars (approximately 823 billion won) in milestone payments associated with the development, approval, and sales of the two products, and will be entitled to royalties based on product sales after commercialization. According to the terms of the agreement, Biogen will also have the option to develop a third product.



Tae Yeon Jeon, CEO of Alteogen, stated, “Biogen is a leading global biotechnology company with strong research and development capabilities. We are very pleased to pursue the development of innovative products for patients together through this partnership.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing